BCM
ALBO

BlueCrest Capital Management’s Albireo Pharma Inc ALBO Stock Holding History

BlueCrest Capital Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-21,775
Closed -$709K – 1931
2018
Q1 		$709K Buy
+21,775
New +$733K 0.02% 597

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BlueCrest Capital Management's ALBO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Albireo Pharma Inc (ALBO) in Q2 2018, closing a stake of 21,775 shares — an estimated $709K sold.

BlueCrest Capital Management first reported a position in ALBO in Q1 2018 and held it in 1 quarter. The position peaked at $709K in Q1 2018. 69 funds tracked by Wall St. Rank hold ALBO as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Albireo Pharma Inc position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 21,775 Albireo Pharma Inc shares in Q2 2018, an estimated $709K.
  • BlueCrest Capital Management first reported a position in Albireo Pharma Inc in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Albireo Pharma Inc position peaked at $709K in Q1 2018.
  • 69 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.